Tax Day Not So Taxing (for Corporations, Housing)

Mark Vickery Published on April 17, 2018

Tuesday, April 17, 2018

Strength in Q1 earnings season, at least in these early stages, has helped bolster market indexes. This continues ahead of Tuesday’s market open as well, with Dow futures looking to wipe out 2018 losses and push back into the green for the first time in roughly 3 weeks.

Ahead of today’s opening bell, new Housing Starts and Permits results for March have hit the tape. We saw a seasonally adjusted, annualized read of 1.32 million new starts last month, up from the 1.26 million estimated, up 1.9%. February starts were revised up from 1.24 million originally reported to 1.295 million today.

Multi-family units were stronger than expected last month, up 14.4% to 452K. Single-family housing starts, which had been carrying the load in recent times, fell 3.7% to 867K. By region, while the Midwest saw gains, the Northeast, South and West took a step backward. Permits — a forward indicator of future housing starts — for multi-family homes spiked up 19% to 514K, suggesting a continuation in multi-family home strength.

Q1 Earnings Highlights

While we await earnings reports after the bell today from IBM, United Continental and others, ahead of the bell we saw results from some key big names across industry lines — and all outperformed expectations:

Wall Street major Goldman Sachs (GS - Free Report) followed the strength from late last week among other big banks, posting earnings of $6.95 per share from the $5.67 expected, as well as up strongly from the year-ago’s $5.15 per share. Revenues reached $10 billion in Q1, easily surpassing the $8.9 billion expected and $8 billion from the year-ago quarter. For more on GS’s earnings, click here.

Zacks Rank #3 (Hold)-rated Johnson & Johnson (JNJ - Free Report) topped earnings estimates by 5 cents to $2.06 per share, as quarterly sales reached $20.0 billion, outpacing the expected $19.5 billion in the Zacks consensus. Pharmaceuticals rose up in the quarter 19.4% year over year to $9.84 billion by itself. Shares are up more than 1% in today’s pre-market. For more on JNJ’s earnings, click here.

UnitedHealth (UNH - Free Report) , which had been carrying a Zacks Rank #4 (Sell) rating going into this morning’s earnings report, also surprised to the upside: $3.04 per share beat the $2.92 the Zacks consensus had been expecting. Revenues of $55.2 billion narrowly topped the $54.9 billion estimated, on healthy subscription growth year over year. For more on UNH’s earnings, click here.

Mark Vickery

Senior Editor

Questions or comments about this article and/or its author? Click here>>

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.